Pemetrexed Disodium (Alimta) will now be available across the NHS for malignant pleural mesothelioma in certain cases after NICE threw out an appeal.

 After a two-and-a-half-year wait because of approval processes NICE has recommended Pemetrexed Disodium for patients who have WHO performance status of 0 (able to carry out all normal activity without restriction) or 1 (restricted in strenuous activity but able to move around and carry out light work), or who are considered to have advanced disease or for whom surgical resection is considered inappropriate.
Mesothelioma is uncurable but the drug can increase life expectancy and reduce symptoms. At present Pemetrexed Disodium is available in certain areas of the country but its prescription is not widespread across the UK.
Dr Gillian Leng, Deputy Chief Executive of NICE said:
“I know that some patients and healthcare professionals have criticised the time it has taken for us to issue guidance. In this instance two separate appeal stages have delayed the publication of our final guidance. However I am confident that we have reached the right conclusion.”
Adrian Budgen, a solicitor specialising in asbestos related diseases said:
"Until now, only a small number of sufferers have qualified for Alimta so there has been a deeply regrettable postcode lottery in existence. Although it is far from being a cure, the patients who respond well to this treatment will have a better quality of life and that can only be a good thing."
 Similar Articles
 Scottish drugs assessment ‘better for patients’
 DAS warn of premium rise
 Insurers challenge PI paper
 RNID report highlights dancers deafness risk
 SRA identifies model working practices
 Premex welcomes agreement on medical reporting agency fees
 Regulation causes downturn for CMCs
 Major threat for ATE insurers
 DCA approves 800 firms
 Claims management regulation comes into force
 Law Society: Triumph for common sense
 ABI welcomes Government congultation
 High Court decision overturned
 Overhaul of Part 36
 Authorisation deadline announced
 Conservatives challenge NHS deficit
 CLAN criticise regulation of third party litigation funders
 DCA consultation date announced
 Consultation on personal injury delayed
 Need for speed
 NHS sets aims to limit exposure to compensation claims
 NHS patient database starts trial
 No "last resort" compensation for Mesothelioma sufferers
 The burden of regulation
 Langdon hearing adjourned
 Claim-chasers will struggle to obtain PI cover
 BMJ argues new regulation could lead to increase in complaints
 Consultation on professional indemnity insurance published
 Medical profession in regulation shake-up
 Claims management – applications for authorisation
 Confusion over regulation rules
 CMCR will have sanctioning powers
 Insurers to be regulated?
 Compensation Bill receives Royal Assent
 DCA to regulate claims managers 
  

Referred from: http://www.legal-medical.co.uk/news/11750.html